Month: April 2020

AS Pro Kapital Grupp informs about a change in investor calendar. Due to the extraordinary situation caused by the spread of coronavirus COVID-19 and the start of reorganisation proceedings in the group’s subsidiary AS Tallinna Moekombinaat, publishing of unaudited interim report for the I quarter 2020 is postponed. Initially planned for 30 April 2020, the interim report will be published on 22 May 2020.Angelika AnnusCFOPhone: +372 6144920e-mail: prokapital@prokapital.ee

MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) — Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the treatment of the rare genetic metabolic disorder erythropoietic protoporphyria (EPP).1It is estimated that 5,000 Chinese residents live with EPP – based on a prevalence of 1:75,000 to 1:211,000 – with no therapy approved prior to SCENESSE®.Under a Named Patient Program, CLINUVEL is collaborating with local partner Winhealth Pharma to facilitate treatment in prominent Chinese hospitals, with patients treated exclusively in selected large medical centres and hospitals. Local subsidies are available to enable eligible EPP patients to receive treatment.EPP is an inherited disorder which causes incapacitating burns and internal damage to vessels...

CALGARY, Alberta, April 23, 2020 (GLOBE NEWSWIRE) — TransGlobe Energy Corporation (“TransGlobe” or the “Company”) (AIM & TSX: “TGL” & NASDAQ: “TGA”) was notified on April 20, 2020 by the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) that the closing bid price of the Company’s common stock for the last 30 consecutive business days from March 6, 2020 to April 17, 2020 did not meet the minimum bid price of $1.00 per share as set forth in Nasdaq Listing Rule 5450(a)(1) required for continued listing on Nasdaq (the “Minimum Bid Requirement”).  Pursuant to the Nasdaq Listing Rules, the Company has been provided with a compliance period of 180 calendar days from the date of notification in which to regain compliance with the Minimum Bid Requirement. Additionally, due to the ongoing volatility in the...

Press releaseMalmö, April 23, 2020Acarix publishes the annual report for 2019Today, Thursday April 23, Acarix is publishing its Annual Report for 2019 on the company website www.acarix.com.The Annual Report is also attached to this press release.For further information, please contact: Per Persson, CEOE-mail per.persson@acarix.comPhone: +46 73 600 59 90Acarix is listed on Nasdaq First North Growth Market in Stockholm.Wildeco Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) is Certified Adviser to Acarix.About Acarix:Acarix was established in 2009 and is listed on Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix’s CADScor®System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-one system...

PressmeddelandeMalmö, 23 april, 2020Acarix publicerar årsredovisningen för 2019Idag, torsdagen den 23 april, publicerar Acarix sin årsredovisning för verksamhetsåret 2019 på bolagets hemsida www.acarix.com.Årsredovisningen finns även bifogad i pressreleasen.För ytterligare information, vänligen kontakta: Per Persson, vdE-mail per.persson@acarix.comTelefon: +46 73 600 59 90Acarix är noterat på Nasdaq First North Growth Market i Stockholm.Wildeco Ekonomisk Information AB (+46 8 545 271 00, info@wildeco.se) är bolagets Certified Adviser.Om AcarixAcarix grundades 2009 och är noterat på Nasdaq First North Premier Growth Market (ticker: ACARIX). Acarix CADScor®System använder en avancerad sensor som placeras på huden ovanför hjärtat för att lyssna på ljudet av hjärtkontraktion och turbulent flöde. Det har utformats för att vara ett allt-i-ett-system...

TORONTO, April 23, 2020 (GLOBE NEWSWIRE) — QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) reports that it has arranged a secured loan in the amount of US$7,700,000 from, and issued a promissory note (the “Note”) to, an arm’s length third party lender (the “Lender”), in order to finance the purchase of 1 million COVID-19 antibody testing kits from South Korean diagnostic testing company PCL Inc., to be distributed in the North and South American markets, and for general corporate purposes. QuestCap submitted an application for approval to Health Canada under the Fast-Track program on April 10, 2020.The Promissory NoteThe Lender will fund US$7,700,000 to QuestCap immediately.The Note provides for security over all of the assets of QuestCap and is due within 60 days from the date of issuance of the Note (subject to...

STOCKHOLM – April 23, 2020 – ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, today announced record sales and EBITDA, mainly driven by the company’s medical imaging business, despite the current global challenges. ContextVision’s first digital pathology solution continues to accelerate toward market availability.Medical ImagingSales in Q1 ended at 29.2 MSEK, a substantial increase of 38.4% compared to the first quarter in 2019. EBITDA was 13,8 MSEK and the operating result ended at 11,8 MSEK, strengthening the liquidity at the end of the quarter. This growth is attributed to both the company’s solid business with existing customers and significant revenue gain from new customer contracts as mentioned in the Company’s February 2020 press release. The recently signed contracts...

STOCKHOLM – 23. april 2020 – ContextVision, et medisinsk teknologiprogramvarefirma som spesialiserer seg på bildeanalyse og kunstig intelligens, har satt ny rekord både på salg og resultat (EBITDA), hovedsakelig drevet av selskapets medisinske bildebehandlingsvirksomhet, til tross for de nåværende globale utfordringene. ContextVisions første digitale patologiløsning fortsetter å akselerere mot markedet.Medisinsk bildebehandlingSalget i første kvartal endte på 29,2 MSEK, en betydelig økning på 38,4 prosent sammenlignet med første kvartal i 2019. EBITDA havnet på 13,8 MSEK, mens driftsresultatet endte på 11,8 MSEK, noe som styrket likviditeten ved utgangen av kvartalet. Denne veksten bidro både til selskapets solide forretning med eksisterende kunder og betydelig inntektsvekst fra kontrakter med nye kunder, som nevnt i selskapets...

LONDON, April 23, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss the financial results and provide a corporate update.To participate, please dial one of the following numbers and reference conference ID 2667888:866-940-4574 for callers in the United States0800 028 8438 for callers in the United Kingdom0800 181 5287 for callers in GermanyA live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will...